In Vitro Stability of Human Fibrinopeptide B

Summary

In anticipation of a future clinical application of plasma fibrinopeptide B (FPB) measurement, we studied the stability of FPB in an ultrafiltrate of normal plasma, normal urine and alkaline buffer by measuring the immunoreactivity of the peptide by FPB radioimmunoassay using anti FPB serum (R-29). FPB was unstable in an ultrafiltrate of plasma and urine and demonstrated a temperature dependent loss of activity. In plasma ultrafiltrate the loss of immunoreactivity was not significant during the first 24 hours, however, 92% of the peptide activity was lost at the end of seven days at 25° C and 37° C. The rate of FPB degradation in urine was comparable. The peptide was stable in an alkaline buffer (pH 8.5) at temperatures ranging from �10° C to 37° C or in plasma ultrafiltrate or urine when incubated at �10° C. Treatment with carboxypeptidase B or leucine aminopep- tidase for two hours at 37° C (enzyme/substrate molar ratio of up to 1:100) did not cause a loss of FPB immunoreactivity. EDTA (1.0 mM) and Trasylol (500 units/ml) completely stabilized the peptide in a plasma ultrafiltrate.

• References

• 1 Bailey K, Bettelheim FR, Lorand L, Middlebrook WR. 1951; Action of thrombin in clotting of fibrinogen. Nature (London) 167: 233
• 2 Bilezihan SB, Nossel HL, Butler Jr VP, Canfield RE. 1975; Radioimmunoassay of human fibrinopeptide B and kinetics of fibrinopeptide cleavage by different enzymes. Journal of Clinical Investigation 56: 438
• 3 Blombäck B, Blombäck M, Edman P, Hessel B. 1966; Human fibrinopeptides. Isolation, characterization and structure. Biochimica et Biophysica Acta 115: 371
• 4 Budzynski AZ, Marder VJ. 1975 Determination of human fibrinopeptide A by radioimmunoassay in purified systems and in the blood. Thrombosis et Diathesis Haemorrhagica. 34.
• 5 Cronlund M, Hardin J, Burton J, Lee L, Haber E, Bloch KJ. 1976; Fibrinopeptide A in plasma of normal subjects and patients with disseminated intravascular coagulation and systemic lupus erythematosus. Journal of Clinical Investigation 58: 142
• 6 Erdos EG, Sloane EM, Wohler IM. 1964 Carboxypeptidase in blood and other body fluids. I. Properties, distribution and partial purification of the enzyme. Biochemical Pharmacology.
• 7 Hunter WM, Greenwood FC. 1962; Preparation of iodine ¹³¹labelled growth hormone of high specific activity. Nature 194: 495
• 8 Kockum C. 1976; Radioimmunoassay of fibrinopeptide A-clinical application. Thrombosis Research 8: 225
• 9 La Gamma KS, Nossel HL. 1978; The stability of fibrinopeptide B immunoreactivity in blood. Thrombosis Research 12: 447
• 10 Nossel HL, Younger LR, Wilner GD, Procupez T, Canfield RE, Butler Jr VP. 1971; Radioimmunoassay of human fibrinopeptide A. Proceedings of National Academv of Science, U.S.A. 68: 2350
• 11 Nossel HL, Yudelman I, Canfield RE, Butler Jr VP, Spanondis K, Wilner GD, Qureshi GD. 1974; Measurement of fibrinopeptide A in human blood. Journal of Clinical Investigation 54: 43
• 12 Nossel HL, Butler Jr VP, Canfield RE, Yudelman I, Ti M, Spanondis K, Soland T. 1975; Potential use of fibrinopeptide A measurements in the diagnosis and management of thrombosis. Thrombosis et Diathesis Haemorrhagica 33: 426
• 13 Qureshi GD, Nossel HL. 1972; Stability studies of human fibrinopeptide A as measured by radioimmunoassay. Proceedings of the Society for Experimental Biology and Medicine 140: 1069
• 14 Teger-Nilsson AC. 1968; Degradation of human fibrinopeptides A and B in blood serum in vitro. Acta Chemica Scandinavica 22: 3171
• 15 Wilner GD, Nossel HL, Canfield RE, Butler Jr VP. 1976; Immunochemical studies of human fibrinopeptide A using synthetic peptide homologues. Biochemistry 15: 1209